Judy Wang

2.1k total citations
49 papers, 1.0k citations indexed

About

Judy Wang is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Judy Wang has authored 49 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Judy Wang's work include Radiopharmaceutical Chemistry and Applications (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and HER2/EGFR in Cancer Research (7 papers). Judy Wang is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and HER2/EGFR in Cancer Research (7 papers). Judy Wang collaborates with scholars based in United States, Canada and Australia. Judy Wang's co-authors include Raymond M. Reilly, Deborah A. Scollard, Paul Chen, Ross Cameron, Katherine A. Vallis, Claire Holloway, Ying Tang, Paul Chen, Harriette J. Kahn and Jeanne S. Mandelblatt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Judy Wang

47 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judy Wang United States	18	437	411	289	131	80	49	1.0k
Jason L.J. Dearling United States	21	308 0.7×	597 1.5×	414 1.4×	190 1.5×	88 1.1×	45	1.2k
Katelyn M. Atkins United States	19	207 0.5×	347 0.8×	198 0.7×	380 2.9×	112 1.4×	78	1.3k
Courtney Brown United States	15	307 0.7×	106 0.3×	366 1.3×	73 0.6×	110 1.4×	46	1.2k
Charles Widström Sweden	20	573 1.3×	1.2k 2.9×	549 1.9×	211 1.6×	72 0.9×	25	1.6k
Jean A. Quinn United Kingdom	23	315 0.7×	149 0.4×	563 1.9×	142 1.1×	108 1.4×	59	1.5k
Mark Westwood United Kingdom	19	308 0.7×	442 1.1×	378 1.3×	163 1.2×	22 0.3×	67	1.6k
Waleed Arafat Egypt	21	388 0.9×	126 0.3×	632 2.2×	134 1.0×	123 1.5×	57	1.2k
Ravi A. Chandra United States	13	336 0.8×	183 0.4×	355 1.2×	216 1.6×	142 1.8×	32	1.3k
Ingo Stoffels Germany	21	357 0.8×	308 0.7×	160 0.6×	108 0.8×	47 0.6×	58	1.3k
Ronald Scheff United States	13	519 1.2×	138 0.3×	161 0.6×	336 2.6×	117 1.5×	26	880

Countries citing papers authored by Judy Wang

Since Specialization

Citations

This map shows the geographic impact of Judy Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy Wang more than expected).

Fields of papers citing papers by Judy Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy Wang. The network helps show where Judy Wang may publish in the future.

Co-authorship network of co-authors of Judy Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Judy Wang. A scholar is included among the top collaborators of Judy Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy Wang. Judy Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naing, Aung, Amit Mahipal, Milind Javle, et al.. (2025). Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. PubMed. 8(1). 71–81.

Yuan, Lin, Meghana Kulkarni, Evan L. Chiswick, et al.. (2025). A novel approach for first‐in‐human dose selection using population dose–response modelling to find a minimum anticipated biological effect level. British Journal of Clinical Pharmacology. 91(9). 2555–2566.

Hecht, J. Randolph, Jean‐Marie Michot, David J. Bajor, et al.. (2025). CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. PubMed. 3(1). 10–10. 1 indexed citations

Yeku, Oladapo, Minal Barve, Winston Tan, et al.. (2025). Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. Journal for ImmunoTherapy of Cancer. 13(3). e010959–e010959. 6 indexed citations

Fu, Siqing, Erika Hamilton, Alexander I. Spira, et al.. (2022). 750 TWT-101: a first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies. Regular and Young Investigator Award Abstracts. A783–A783. 3 indexed citations

Wang, Judy, et al.. (2021). Evaluation of Clinical Outcomes Following Minor Amputations in Australia – An Important Consideration for Timing of Revascularisation. Annals of Vascular Surgery. 76. 389–398. 1 indexed citations

Hoffmann, Jan, Silke Miller, Margarida Martins-Oliveira, et al.. (2020). PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?. Pain. 161(7). 1670–1681. 51 indexed citations

Cioccari, Luca, Laurent Bitker, Douglas F. Hacking, et al.. (2020). Prolonged postoperative cerebral oxygen desaturation after cardiac surgery. European Journal of Anaesthesiology. 38(9). 966–974. 3 indexed citations

Wang, Judy, et al.. (2020). Intravascular ultrasound-guided laparoscopic division of the median arcuate ligament. Journal of Vascular Surgery Cases and Innovative Techniques. 6(1). 147–151. 3 indexed citations

10.

Lee, Valerie, Judy Wang, Marianna Zahurak, et al.. (2018). A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Clinical Cancer Research. 24(24). 6160–6167. 39 indexed citations

11.

Wang, Judy, et al.. (2018). Endovascular embolization of a giant hepatic artery aneurysm. ANZ Journal of Surgery. 89(12). 1666–1668. 2 indexed citations

12.

Maingard, Julian, Hong Kuan Kok, Judy Wang, et al.. (2018). Endovascular Retrieval of Dislodged Neurovascular Devices with a Stentriever: Case Series and Technical Review. World Neurosurgery. 123. e661–e669. 5 indexed citations

13.

Sheppard, Vanessa B., Judy Wang, Bin Yi, et al.. (2008). Are Health-care Relationships Important for Mammography Adherence in Latinas?. Journal of General Internal Medicine. 23(12). 2024–2030. 50 indexed citations

14.

Chen, Paul, Judy Wang, Kristin J. Hope, et al.. (2006). Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.. PubMed. 47(5). 827–36. 81 indexed citations

15.

Tang, Ying, Deborah A. Scollard, Paul Chen, et al.. (2005). Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nuclear Medicine Communications. 26(5). 427–432. 52 indexed citations

16.

Tang, Ying, Judy Wang, Deborah A. Scollard, et al.. (2005). Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nuclear Medicine and Biology. 32(1). 51–58. 116 indexed citations

17.

Chen, Paul, et al.. (2005). Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. European Journal of Nuclear Medicine and Molecular Imaging. 33(3). 301–310. 34 indexed citations

18.

Wang, Judy, et al.. (2003). Antisense imaging of epidermal growth factor-induced p21 WAF-1/CIP-1 gene expression in MDA-MB-468 human breast cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging. 30(9). 1273–1280. 14 indexed citations

19.

Wang, Judy, Raymond M. Reilly, Paul Chen, et al.. (2002). Fusion of the C _H 1 Domain of IgG ₁ to Epidermal Growth Factor (EGF) Prolongs its Retention in the Blood but Does Not Increase Tumor Uptake. Cancer Biotherapy and Radiopharmaceuticals. 17(6). 665–671. 3 indexed citations

20.

Wang, Judy, Paul Chen, Zi-Fen Su, et al.. (2001). Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nuclear Medicine and Biology. 28(8). 895–902. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact